What is SK Biopharmaceuticals' market capitalization in US dollars?
SK Biopharmaceuticals, a prominent South Korean innovative healthcare and pharmaceutical enterprise listed on the Korea Exchange, maintains a market capitalization fluctuating around 4.2 billion to 4.5 billion US dollars. This corporate equity valuation is driven by investor assessments of its global commercialized central nervous system therapeutics, epilepsy drug portfolio, and continuous research pipelines.
Related FAQs
SK Finance operates primarily as a non-banking financial company focusing on vehicle financing and micro, small, and medium enterprise loans.
Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) trades at a market price of approximately $21.53 per share.
Day One Biopharmaceuticals achieved significant clinical and corporate milestones with the advancement of its lead targeted oncology therapies, highlighted by regulatory submissions and commercialization efforts for pediatric brain cancer treatments.
SK Bioscience Co., Ltd. operates as a key biotechnology and vaccine-manufacturing subsidiary of SK discovery, which functions as the intermediate holding company under South Korea's massive SK Group conglomerate.
SK Finance Limited is widely regarded as a well-established and reputable non-banking financial company in India, specializing in vehicle financing and micro, small, and medium enterprise lending.
SK Group is the second-largest chaebol (conglomerate) in South Korea, comprising over a hundred subsidiary and affiliate companies operating across advanced technology, energy, telecommunications, and biotechnology.
SK Pharma generally refers to the pharmaceutical and life sciences business sectors managed under the broader umbrella of South Korea's SK Group, encompassing specialized corporate entities like SK Biopharmaceuticals and SK bioscience.
SK Bioscience played a direct and notable role in the global response to the pandemic by developing Skycovione, which marked South Korea's first domestically produced COVID-19 vaccine utilizing advanced protein subunit technology.
SK bioscience Co., Ltd. is publicly traded on the Korea Exchange under the official stock ticker symbol 302440.
SK Life Sciences, operating as the United States subsidiary of SK Biopharmaceuticals, generates multi-million-dollar annual revenues driven primarily by the commercialization and prescription sales of its flagship central nervous system medications a...
SK Group is one of the largest multinational conglomerates, operating diverse business subsidiaries across energy, chemicals, telecommunications, and advanced technology sectors.